Immune cell study could unlock new COVID-19 treatments
NCT ID NCT04590261
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study looks at specific immune cells called myeloid cells in people who were hospitalized with COVID-19 pneumonia. Researchers want to understand how these cells respond to the virus and whether certain cell types can predict how sick a person gets. The goal is to find new ways to treat or prevent severe COVID-19 by targeting these immune responses.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could identify new treatment targets for severe COVID-19 and markers to predict patient outcomes.
- What could go wrong
- This is an observational study, not a treatment trial. Findings may not directly lead to therapies, and results may not apply to all COVID-19 patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Started
-
Sep 2023
- Finished
-
Sep 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \> 18 years * Sex : male or female * French Social Security insurance * Information and consent dated and signed \* * Group 1 : inclusion 2 to 12 months after hospitalization for Covid-19 pneumonia with mild severity (oxygen treatment ≤5L/mn); * Group 2 : 2 to 12 months after hospitalization for Covid-19 pneumonia with high severity (oxygen treatment \>5L/mn); * Group 3 : external visit at Cochin Hospital, age- and sex -matched with Groups 1, 2, 4. * Group 4 : inclusion during hospitalization for Covid-19, within the first month of symptoms. Exclusion Criteria: * Tuberculosis or other evolutive bacterial infection * Chronic evolutive viral Infections (Hepatitis B or C, HIV) * Ongoing chemotherapy or radiotherapy * Participation in another research protocol with current exclusion period at the time of pre-inclusion (possible inclusion in an observational study * Vulnerable person (pregnant, parturient woman, breastfeeding woman, person Under tutorship, person under arrest through judiciary or administrative decision )
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19; SARS-COV2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.